Amid growing global interest in RNA interference therapeutics and using newly licensed in N-Acetylgalactosamine (GalNAc) conjugation technology, OliX Pharmaceuticals, Inc. is emerging as a potential dark horse for partnerships in the field.
The clinical stage South Korean venture is developing therapeutics against a variety of disorders by down-regulating expression of disease-causing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?